MRVI Maravai Lifesciences Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRVI

Price (delayed)

$7.37

Market cap

$1.91B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.52

Enterprise value

$2.02B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 29
Highlights
Maravai Lifesciences Holdings's EPS has soared by 61% YoY and by 27% from the previous quarter
MRVI's net income has surged by 60% year-on-year and by 26% since the previous quarter
Maravai Lifesciences Holdings's quick ratio has decreased by 44% QoQ and by 38% YoY
The company's equity fell by 23% YoY and by 3.3% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.maravai.com
Peers: NVAX NVCR NBIX

Key stats

What are the main financial stats of MRVI

MRVI stock price

How has the Maravai Lifesciences Holdings stock price performed over time
Intraday
-1.21%
1 week
7.75%
1 month
-14.7%
1 year
168.98%
YTD
126.77%
QTD
18.11%

Financial performance

How have Maravai Lifesciences Holdings's revenue and profit performed over time
Revenue
$208.78M
Gross profit
$72.85M
Operating income
-$117.01M
Net income
-$77.39M
Gross margin
34.9%
Net margin
-37.1%
The operating income has surged by 63% year-on-year and by 30% since the previous quarter
The operating margin has soared by 61% YoY and by 32% from the previous quarter
MRVI's net income has surged by 60% year-on-year and by 26% since the previous quarter
The company's net margin has surged by 58% YoY and by 27% QoQ

Price vs fundamentals

How does MRVI's price correlate with its fundamentals

Growth

What is Maravai Lifesciences Holdings's growth rate over time

Valuation

What is Maravai Lifesciences Holdings stock price valuation
MRVI P/E details
P/E
N/A
P/B
9.3
P/S
5.22
EV/EBIT
N/A
EV/EBITDA
741.7
EV/Sales
9.68
Maravai Lifesciences Holdings's EPS has soared by 61% YoY and by 27% from the previous quarter
MRVI's price to book (P/B) is 105% more than its last 4 quarters average of 4.6 but 4.9% less than its 5-year quarterly average of 9.9
The company's equity fell by 23% YoY and by 3.3% QoQ
The price to sales (P/S) is 89% more than the last 4 quarters average of 2.8 and 51% more than the 5-year quarterly average of 3.5
Maravai Lifesciences Holdings's revenue has decreased by 5% YoY

Efficiency

How efficient is Maravai Lifesciences Holdings business performance
Maravai Lifesciences Holdings's ROS has soared by 64% YoY and by 36% from the previous quarter
The company's return on invested capital has surged by 57% YoY and by 31% QoQ
The return on assets has grown by 44% year-on-year and by 19% since the previous quarter
The return on equity is up by 43% year-on-year and by 21% since the previous quarter

Dividends

What is MRVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRVI.

Financial health

How did Maravai Lifesciences Holdings financials performed over time
MRVI's total assets is 143% greater than its total liabilities
Maravai Lifesciences Holdings's quick ratio has decreased by 44% QoQ and by 38% YoY
The total liabilities has decreased by 42% YoY and by 28% from the previous quarter
The company's debt is 14% lower than its equity
The company's debt fell by 46% YoY and by 35% QoQ
Maravai Lifesciences Holdings's debt to equity has decreased by 33% QoQ and by 30% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.